BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015;126:300-10. [PMID: 26031917 DOI: 10.1182/blood-2015-03-575365] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Fei F, Ma T, Zhou X, Zheng M, Cao B, Li J. Metabolic markers for diagnosis and risk-prediction of multiple myeloma. Life Sci 2021;265:118852. [PMID: 33278388 DOI: 10.1016/j.lfs.2020.118852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, Curtis DJ, Patil S, Das T, Klarica D, Morgan S, Muirhead J, Gorniak M, Reynolds J, Spencer A. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplant 2017;52:839-45. [DOI: 10.1038/bmt.2017.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Braham MV, Deshantri AK, Minnema MC, Öner FC, Schiffelers RM, Fens MH, Alblas J. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma. Int J Nanomedicine 2018;13:8105-18. [PMID: 30555229 DOI: 10.2147/IJN.S184262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mikhael J. Treatment Options for Triple-class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 2020;20:1-7. [DOI: 10.1016/j.clml.2019.09.621] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
5 Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 2018;32:996-1002. [PMID: 29158558 DOI: 10.1038/leu.2017.334] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
6 Anderson KC. Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv 2017;1:517-21. [PMID: 29296970 DOI: 10.1182/bloodadvances.2016000117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
7 Fuchs O. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. CHDDT 2019;19:51-78. [DOI: 10.2174/1871529x18666180522073855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
8 Muraoka H, Yoshimura C, Kawabata R, Tsuji S, Hashimoto A, Ochiiwa H, Nakagawa F, Fujioka Y, Matsuo K, Ohkubo S. Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways. Cancer Sci 2019;110:3802-10. [PMID: 31583781 DOI: 10.1111/cas.14209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
9 Li M, Qi L, Xu JB, Zhong LY, Chan S, Chen SN, Shao XR, Zheng LY, Dong ZX, Fang TL, Mai ZY, Li J, Zheng Y, Zhang XD. Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma. Mol Ther Oncolytics 2020;19:197-207. [PMID: 33251332 DOI: 10.1016/j.omto.2020.10.004] [Reference Citation Analysis]
10 Anreddy N, Hazlehurst LA. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. J Cell Biochem 2017;118:15-25. [PMID: 27261328 DOI: 10.1002/jcb.25617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
11 Zhang K, Desai A, Zeng D, Gong T, Lu P, Wang M. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 2017;8:10748-59. [PMID: 27863374 DOI: 10.18632/oncotarget.13314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
12 Würth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri F. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today 2016;21:190-9. [PMID: 26456577 DOI: 10.1016/j.drudis.2015.09.017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 10.7] [Reference Citation Analysis]
13 Gutiérrez-González A, Martínez-Moreno M, Samaniego R, Arellano-Sánchez N, Salinas-Muñoz L, Relloso M, Valeri A, Martínez-López J, Corbí ÁL, Hidalgo A, García-Pardo Á, Teixidó J, Sánchez-Mateos P. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood 2016;128:2241-52. [PMID: 27625360 DOI: 10.1182/blood-2016-01-695395] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
14 Reale A, Khong T, Mithraprabhu S, Savvidou I, Hocking J, Bergin K, Ramachandran M, Chen M, Dammacco F, Ria R, Silvestris F, Vacca A, Reynolds J, Spencer A. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leuk Lymphoma 2021;62:337-47. [PMID: 33131357 DOI: 10.1080/10428194.2020.1832659] [Reference Citation Analysis]
15 Jelinek T, Hajek R. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Blood Rev 2016;30:101-10. [PMID: 26362528 DOI: 10.1016/j.blre.2015.08.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
16 Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes 2018;2:16. [PMID: 30761216 DOI: 10.3390/epigenomes2030016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
17 Ide T, Osawa M, Sanghavi K, Vezina HE. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. Cancer Chemother Pharmacol 2021. [PMID: 34825942 DOI: 10.1007/s00280-021-04365-4] [Reference Citation Analysis]
18 Maes A, Menu E, Veirman K, Maes K, Vand Erkerken K, De Bruyne E. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget 2017;8:90501-20. [PMID: 29163849 DOI: 10.18632/oncotarget.18765] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
19 Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Manag Res 2017;9:307-14. [PMID: 28744161 DOI: 10.2147/CMAR.S117477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 El Arfani C, De Veirman K, Maes K, De Bruyne E, Menu E. Metabolic Features of Multiple Myeloma. Int J Mol Sci 2018;19:E1200. [PMID: 29662010 DOI: 10.3390/ijms19041200] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
21 Jung SH, Lee HJ, Vo MC, Kim HJ, Lee JJ. Immunotherapy for the treatment of multiple myeloma. Crit Rev Oncol Hematol 2017;111:87-93. [PMID: 28259300 DOI: 10.1016/j.critrevonc.2017.01.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
22 Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E, Terrazas C, Satoskar AR, Gunes EG, Dona A, Sanchez JF, Bergsagel PL, Chesi M, Pozhitkov A, Rosen S, Marcucci G, Keats JJ, Hofmeister CC, Krishnan A, Caserta E, Pichiorri F. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight 2019;4:129348. [PMID: 31593552 DOI: 10.1172/jci.insight.129348] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
23 Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, Ocheni S, Theurich S, Kuhr K, Scheckel B, Adams A, Skoetz N. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2019;2019. [PMID: 31765002 DOI: 10.1002/14651858.CD013487] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Tong J, Yu Q, Xu W, Yu W, Wu C, Wu Y, Yan H. Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway. Cancer Biol Ther 2019;20:381-90. [PMID: 30359543 DOI: 10.1080/15384047.2018.1529112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O’gorman P. Maintenance and continuous therapy for multiple myeloma. Expert Review of Anticancer Therapy 2018;18:751-64. [DOI: 10.1080/14737140.2018.1490181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
26 Avet-Loiseau H, Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia 2018;32:1267-76. [PMID: 29720731 DOI: 10.1038/s41375-018-0098-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kumar R, Gupta N, Himani, Sharma A. Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules. Mol Biol Rep 2018;45:2429-39. [DOI: 10.1007/s11033-018-4409-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Feng Y, Liu X, Li X, Zhou Y, Song Z, Zhang J, Shi B, Wang J. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. Oncoimmunology 2021;10:1959102. [PMID: 34434610 DOI: 10.1080/2162402X.2021.1959102] [Reference Citation Analysis]
29 Patel DA, Gopalakrishnan R, Engelhardt BG, McArthur E, Sengsayadeth S, Culos KA, Byrne M, Goodman S, Savani BN, Chinratanalab W, Jagasia M, Mosse CA, Cornell RF, Kassim AA. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplant 2020;55:1137-46. [PMID: 31992845 DOI: 10.1038/s41409-020-0791-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Montefusco V, Corso A, Galli M, Ardoino I, Pezzatti S, Carniti C, Patriarca F, Gherlinzoni F, Zambello R, Sammassimo S, Marcatti M, Nozza A, Crippa C, Cafro AM, Baldini L, Corradini P. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. Br J Haematol 2020;188:907-17. [DOI: 10.1111/bjh.16287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Devine H, Verina D. Young Adults with Multiple Myeloma. Seminars in Oncology Nursing 2017;33:316-31. [DOI: 10.1016/j.soncn.2017.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
32 Xiong S, Chng WJ, Zhou J. Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma. Cell Mol Life Sci 2021;78:3883-906. [PMID: 33599798 DOI: 10.1007/s00018-021-03756-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Furumaki H, Takeshita A, Ohto H, Yamada C, Fujihara H, Ishizuka K, Shibata H, Shinba T, Nemoto N, Ino K, Ozawa A, Watanabe H, Kawabata K, Obata Y. A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells. Vox Sang 2021;116:725-34. [PMID: 33314130 DOI: 10.1111/vox.13052] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Zang M, Guo J, Liu L, Jin F, Feng X, An G, Qin X, Wu Y, Lei Q, Meng B, Zhu Y, Guan Y, Deng S, Hao M, Xu Y, Zou D, Wu M, Qiu L, Zhou W. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis 2020;9:31. [PMID: 32139666 DOI: 10.1038/s41389-020-0216-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Papadas A, Asimakopoulos F. Mechanisms of Resistance in Multiple Myeloma. In: Mandalà M, Romano E, editors. Mechanisms of Drug Resistance in Cancer Therapy. Cham: Springer International Publishing; 2018. pp. 251-88. [DOI: 10.1007/164_2017_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
36 Abramson HN. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci 2018;19:E3924. [PMID: 30544512 DOI: 10.3390/ijms19123924] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
37 Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Target Oncol 2017;12:643-54. [PMID: 28803351 DOI: 10.1007/s11523-017-0524-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
38 Ryu J, Koh Y, Park H, Kim DY, Kim DC, Byun JM, Lee HJ, Yoon SS. Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. Mol Cells 2016;39:898-908. [PMID: 28008160 DOI: 10.14348/molcells.2016.0210] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
39 Markus E, Trestman S, Cohen Y, Angel Y, Sofer Y, Mittelman M, Avivi I, Stern N, Izkhakov E. Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. BMC Cancer 2020;20:489. [PMID: 32473631 DOI: 10.1186/s12885-020-06976-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Wuillème S, Lok A, Robillard N, Dupuis P, Stocco V, Migné H, Dusquesne A, Touzeau C, Tiab M, Béné MC, Moreau P. Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2016;51:1143-5. [PMID: 27042840 DOI: 10.1038/bmt.2016.74] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
41 Richardson PG, Holstein SA, Schlossman RL, Anderson KC, Attal M, Mccarthy PL. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy 2017;18:1975-85. [DOI: 10.1080/14656566.2017.1409207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 Venken K, Favreau M, Gaublomme D, Menu E, Vanderkerken K, Elewaut D. Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function? Mol Immunol 2018;101:521-6. [PMID: 30153633 DOI: 10.1016/j.molimm.2018.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Yu Z, Li T, Wang C, Deng S, Zhang B, Huo X, Zhang B, Wang X, Zhong Y, Ma X. Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells. Oncotarget 2016;7:15725-37. [PMID: 26894970 DOI: 10.18632/oncotarget.7398] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
44 Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol 2018;180:821-30. [PMID: 29435979 DOI: 10.1111/bjh.15058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
45 Schneiderova P, Pika T, Gajdos P, Fillerova R, Kromer P, Kudelka M, Minarik J, Papajik T, Scudla V, Kriegova E. Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. Oncotarget 2017;8:69408-21. [PMID: 29050213 DOI: 10.18632/oncotarget.11242] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
46 Zhai B, Hou C, Xu R, Fang Y, Ma N, Xing C, Wang X, Xiao H, Chen G, Han G, Wang R. Gm6377 suppressed SP 2/0 xenograft tumor by down-regulating Myc transcription. Clin Transl Oncol 2020;22:1463-71. [PMID: 31950438 DOI: 10.1007/s12094-019-02280-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Parchment RE, Voth AR, Doroshow JH, Berzofsky JA. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Semin Oncol 2016;43:501-13. [PMID: 27663482 DOI: 10.1053/j.seminoncol.2016.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
48 Braham MVJ, Minnema MC, Aarts T, Sebestyen Z, Straetemans T, Vyborova A, Kuball J, Öner FC, Robin C, Alblas J. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology 2018;7:e1434465. [PMID: 29872571 DOI: 10.1080/2162402X.2018.1434465] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
49 Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31:2094-103. [PMID: 28104919 DOI: 10.1038/leu.2017.29] [Cited by in Crossref: 239] [Cited by in F6Publishing: 232] [Article Influence: 47.8] [Reference Citation Analysis]
50 Anderson KC. Vision Statement for Multiple Myeloma: Future Directions. Cancer Treat Res 2016;169:15-22. [PMID: 27696255 DOI: 10.1007/978-3-319-40320-5_2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Pasca S, Tomuleasa C, Teodorescu P, Ghiaur G, Dima D, Moisoiu V, Berce C, Stefan C, Ciechanover A, Einsele H. KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma. Front Oncol 2019;9:1137. [PMID: 31709194 DOI: 10.3389/fonc.2019.01137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Cavo M. Together for better? Blood 2016;127:375-6. [PMID: 26823507 DOI: 10.1182/blood-2015-11-678524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Bianchi G, Anderson KC. Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J 2019;25:11-8. [DOI: 10.1097/ppo.0000000000000349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
54 Bangalore-Prakash P, Stunz LL, Mambetsariev N, Whillock AL, Hostager BS, Bishop GA. The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency. Blood Adv 2017;1:2712-23. [PMID: 29296923 DOI: 10.1182/bloodadvances.2017009670] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
55 Driscoll JJ, Brailey M. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. Cancer Metastasis Rev 2017;36:585-98. [PMID: 29052093 DOI: 10.1007/s10555-017-9698-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
56 Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia 2017;19:772-80. [PMID: 28863346 DOI: 10.1016/j.neo.2017.07.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
57 Guang MHZ, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O'Gorman P, McCann A. Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel) 2019;11:E66. [PMID: 30634515 DOI: 10.3390/cancers11010066] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
58 Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant 2017;32:770-80. [PMID: 27540044 DOI: 10.1093/ndt/gfw305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
59 Ammannagari N, Celotto K, Neppalli V, Lee K, Holstein SA. Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies. Clin Lymphoma Myeloma Leuk 2016;16:e129-31. [PMID: 27375159 DOI: 10.1016/j.clml.2016.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma 2018;59:542-61. [PMID: 28610537 DOI: 10.1080/10428194.2017.1337115] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]